ESR1 and breast carcinoma: These findings suggest that a major molecular mechanism by which apo-ER supports basal cell division in hormone-sensitive breast cancer cells may not be sensitive to conventional RAR ligands (agonists), but would be predictably opposed by specific inactivators or down-regulators of RARα1.